Chinese Drug can be Used in Combination with Monoclonal Antibody Medicines to Reduce the Side Effects of COVID- 19
Received Date: Aug 03, 2022 / Accepted Date: Aug 25, 2022 / Published Date: Aug 31, 2022
Abstract
The mortality rate of the recent global epidemic corona virus disease 2019(COVID- 19) is presently as high as 7%.The SARS- CoV- 2 contagion is the malefactor behind COVID- 19. SARS- CoV- 2 is an enveloped single- stranded RNA contagion; the genome encodes four types of the structural proteins S protein, E protein (envelope protein),M protein (matrix protein) and N protein (nucleocapsid protein). In COVID- 19, monoclonal antibodies have played a significant part in opinion and treatment. This composition compactly introduced the development of monoclonal antibodies targeting on S protein and N protein, which represents the main direction of monoclonal antibody medicines used in the opinion and treatment of COVID- 19. Meanwhile, the traditional Chinese drug also plays important part in the fight against COVID- 19 by regulating human immunity. The composition introduced the use of traditional Chinese drug in fighting against COVID- 19.
Citation: Wallace R (2022) Chinese Drug can be Used in Combination with Monoclonal Antibody Medicines to Reduce the Side Effects of COVID- 19. J Tradit Med Clin Natur, 11: 339. Doi: 10.4172/2573-4555.1000339
Copyright: © 2022 Wallace R. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Recommended Journals
Open Access Journals
Article Tools
Article Usage
- Total views: 1171
- [From(publication date): 0-2022 - Dec 22, 2024]
- Breakdown by view type
- HTML page views: 971
- PDF downloads: 200
